Pharmaceutical Industry Reports

Reports > Pharmaceutical > Selected Report

Global Fragile X Syndrome Market Report for Period 2017 till 2023

Single User: $0
Multiple User: $0
Enterprise User: $0


Report Summary:

In this report, the global Fragile X Syndrome market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Fragile X Syndrome in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India
Global Fragile X Syndrome market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Ovid Therapeutics Inc.
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Clinic
Hopital
Research Center

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents / Index:

Table of Contents

Global Fragile X Syndrome Market Research Report 2017
1 Fragile X Syndrome Market Overview
1.1 Product Overview and Scope of Fragile X Syndrome
1.2 Fragile X Syndrome Segment by Type (Product Category)
1.2.1 Global Fragile X Syndrome Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
1.2.2 Global Fragile X Syndrome Production Market Share by Type (Product Category) in 2016
1.2.3 ACT-01
1.2.4 AMO-01
1.2.5 ANAVEX-273
1.2.6 AUT-00206
1.2.7 Bryostatin-1
1.2.8 Cannabidiol
1.2.9 Others
1.3 Global Fragile X Syndrome Segment by Application
1.3.1 Fragile X Syndrome Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Clinic
1.3.3 Hopital
1.3.4 Research Center
1.4 Global Fragile X Syndrome Market by Region (2012-2022)
1.4.1 Global Fragile X Syndrome Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Fragile X Syndrome (2012-2022)
1.5.1 Global Fragile X Syndrome Revenue Status and Outlook (2012-2022)
1.5.2 Global Fragile X Syndrome Capacity, Production Status and Outlook (2012-2022)

2 Global Fragile X Syndrome Market Competition by Manufacturers
2.1 Global Fragile X Syndrome Capacity, Production and Share by Manufacturers (2012-2017)
2.1.1 Global Fragile X Syndrome Capacity and Share by Manufacturers (2012-2017)
2.1.2 Global Fragile X Syndrome Production and Share by Manufacturers (2012-2017)
2.2 Global Fragile X Syndrome Revenue and Share by Manufacturers (2012-2017)
2.3 Global Fragile X Syndrome Average Price by Manufacturers (2012-2017)
2.4 Manufacturers Fragile X Syndrome Manufacturing Base Distribution, Sales Area and Product Type
2.5 Fragile X Syndrome Market Competitive Situation and Trends
2.5.1 Fragile X Syndrome Market Concentration Rate
2.5.2 Fragile X Syndrome Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Fragile X Syndrome Capacity, Production, Revenue (Value) by Region (2012-2017)
3.1 Global Fragile X Syndrome Capacity and Market Share by Region (2012-2017)
3.2 Global Fragile X Syndrome Production and Market Share by Region (2012-2017)
3.3 Global Fragile X Syndrome Revenue (Value) and Market Share by Region (2012-2017)
3.4 Global Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.5 North America Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.6 Europe Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.7 China Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.8 Japan Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.9 Southeast Asia Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.10 India Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Fragile X Syndrome Supply (Production), Consumption, Export, Import by Region (2012-2017)
4.1 Global Fragile X Syndrome Consumption by Region (2012-2017)
4.2 North America Fragile X Syndrome Production, Consumption, Export, Import (2012-2017)
4.3 Europe Fragile X Syndrome Production, Consumption, Export, Import (2012-2017)
4.4 China Fragile X Syndrome Production, Consumption, Export, Import (2012-2017)
4.5 Japan Fragile X Syndrome Production, Consumption, Export, Import (2012-2017)
4.6 Southeast Asia Fragile X Syndrome Production, Consumption, Export, Import (2012-2017)
4.7 India Fragile X Syndrome Production, Consumption, Export, Import (2012-2017)

5 Global Fragile X Syndrome Production, Revenue (Value), Price Trend by Type
5.1 Global Fragile X Syndrome Production and Market Share by Type (2012-2017)
5.2 Global Fragile X Syndrome Revenue and Market Share by Type (2012-2017)
5.3 Global Fragile X Syndrome Price by Type (2012-2017)
5.4 Global Fragile X Syndrome Production Growth by Type (2012-2017)

6 Global Fragile X Syndrome Market Analysis by Application
6.1 Global Fragile X Syndrome Consumption and Market Share by Application (2012-2017)
6.2 Global Fragile X Syndrome Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

7 Global Fragile X Syndrome Manufacturers Profiles/Analysis
7.1 Aelis Farma SAS
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Fragile X Syndrome Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Aelis Farma SAS Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Alcobra Ltd
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Fragile X Syndrome Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Alcobra Ltd Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 AMO Pharma Limited
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Fragile X Syndrome Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 AMO Pharma Limited Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 Confluence Pharmaceuticals LLC
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Fragile X Syndrome Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 Eli Lilly and Company
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Fragile X Syndrome Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Eli Lilly and Company Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Fragile X Syndrome Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Marinus Pharmaceuticals, Inc.
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Fragile X Syndrome Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 MI.TO. Technology S.r.L.
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Fragile X Syndrome Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Neuren Pharmaceuticals Limited
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Fragile X Syndrome Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview
7.10 Ovid Therapeutics Inc.
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Fragile X Syndrome Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.10.4 Main Business/Business Overview
7.11 Sage Therapeutics, Inc.
7.12 Zynerba Pharmaceuticals, Inc.

8 Fragile X Syndrome Manufacturing Cost Analysis
8.1 Fragile X Syndrome Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Fragile X Syndrome

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Fragile X Syndrome Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Fragile X Syndrome Major Manufacturers in 2015
9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 Global Fragile X Syndrome Market Forecast (2017-2022)
12.1 Global Fragile X Syndrome Capacity, Production, Revenue Forecast (2017-2022)
12.1.1 Global Fragile X Syndrome Capacity, Production and Growth Rate Forecast (2017-2022)
12.1.2 Global Fragile X Syndrome Revenue and Growth Rate Forecast (2017-2022)
12.1.3 Global Fragile X Syndrome Price and Trend Forecast (2017-2022)
12.2 Global Fragile X Syndrome Production, Consumption , Import and Export Forecast by Region (2017-2022)
12.2.1 North America Fragile X Syndrome Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.2 Europe Fragile X Syndrome Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.3 China Fragile X Syndrome Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.4 Japan Fragile X Syndrome Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.5 Southeast Asia Fragile X Syndrome Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.2.6 India Fragile X Syndrome Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
12.3 Global Fragile X Syndrome Production, Revenue and Price Forecast by Type (2017-2022)
12.4 Global Fragile X Syndrome Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer


Research Methodology

The market research report added recently to collection of Market Reports Company is based on detailed qualitative and quantitative analysis. The research report is a blend of both bottom up and top down research with the help of which quantitative aspects of the market are determined. Besides this various statistical models, projection techniques and sampling techniques are implemented for quantitative analysis.
The qualitative analysis includes through interactive study with all major industry participants across the industrial value chain. The analysis includes extensive interviews with raw material suppliers, experienced front line staff, directors, CEOs, distributors, major manufacturers, industry experts and end-users. Interaction are usually done with the help of primary interviews, surveys, and vendor briefings. All major factors that influence this market are studied in this research report. The market size for top level markets and sub-segments is normalized, and the impact of various macro and micro economic factors are analyzed during market forecast.

Secondary Research
Secondary sources play a vital role in collection of raw data. Various paid and open access data sources are referred for collection for secondary data. Some of the major secondary data sources referred include:

■ Press releases, annual reports, Non-Profit organizations
■ Industry associations, governmental agencies and customs data
■ Directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), etc.

Primary Research
In Primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Some of the major primary sources include:

■ Product manufacturers
■ Opinion leaders, industry experts and research institutions
■ Distributors, Dealer and Traders
■ Raw Materials suppliers and producers etc.

The data collected through secondary research is validated with the help of primary research respondents.

Data Models
Wherever no credible data sources are available, various data models are implemented which help to develop wide data sets.

Request a Sample of this Report

Please fill out the details requested below.
Our representative will contact you within 1 hour.


Name:


Email ID:


Name of Company:


Designation/Role:


Country:


Message:


Please Enter Captcha Below:

Report Details:



Report ID: 37960

Category: 16

Published date: 2017-12-03 20:12:16

Number of Pages: 111

Publisher Name:

Over all Rating: 0 % (Average of Ratings provided by clients)